Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison

[1]  T. Yankeelov,et al.  NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  V. Kataja,et al.  S24 Update of the FINHER trial based on 5 years of follow-up , 2009 .

[3]  D. Radice,et al.  Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  柏葉 匡寛.  What's going on HER2過剰発現転移性乳がんに対するトラスツズマブとビノレルビンあるいはタキサン併用療法試験[Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP 'Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane , 2007 .

[5]  E. Winer,et al.  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2‐overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study , 2007, Cancer.

[6]  A. Chan,et al.  A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Sommer,et al.  Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial , 2006, British Journal of Cancer.

[8]  M. Mano.  Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy. , 2006, Cancer treatment reviews.

[9]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[10]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[11]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[12]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Slamon,et al.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.

[14]  F. Montemurro,et al.  A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer , 2004, Oncology.

[15]  F. Montemurro,et al.  Trastuzumab-based combination therapy for breast cancer , 2004, Expert opinion on pharmacotherapy.

[16]  E. Winer,et al.  Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Lemarié,et al.  Oral vinorelbine: feasibility and safety profile. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[20]  T. Delozier,et al.  Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Treatment , 1963 .

[22]  V. Knick,et al.  P-Glycoprotein mediated resistance to 5′-nor-anhydro-vinblastine (Navelbine®) , 2007, Investigational New Drugs.

[23]  D. Birnbaum,et al.  BMC Cancer , 2003 .

[24]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.